DrugBank

JULY 18, 2024

For instance, the influenza virus is notorious for its ability to undergo antigenic drift, accumulating mutations in its surface proteins that can render existing vaccines less effective.  These epitopes serve as the primary targets for the immune system, triggering a response that protects against future infection.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

The Pharma Data

DECEMBER 15, 2020

Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. from the Oregon Health & Science University in Portland, and colleagues updated the 2014 HBV screening review in nonpregnant adolescents and adults.

Virus 52

Virus Therapies Trials Treatment 52

Drug Target Review

SEPTEMBER 4, 2023

Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. We discovered it is highly effective and environmentally friendly. Carolina, B.M.,

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

NOVEMBER 13, 2020

If not enough children are immunized against polio, the weakened virus can pass between individuals and over time genetically revert to a form that can cause paralysis. If not enough children are immunized against polio, the weakened virus can pass between individuals and over time genetically revert to a form that can cause paralysis.

Vaccine 52

Vaccine Virus Clinical Trials Licensing 52

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Founded by its Chairman and Chief Executive Officer, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is headquartered in Boston, MA.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

STRASBOURG, France–( BUSINESS WIRE )– Regulatory News: Transgene SA (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the appointment of Hedi Ben Brahim as the Company’s new Chairman and CEO, effective January 1 st , 2021.

Virus 52

Virus Vaccine Treatment Therapies 52

Broad Institute

JANUARY 5, 2024

MIA About Current Schedule Video Playlist Resources All talks Contact us MIA Talks Search - Any - Spring 2024 Fall 2023 Spring 2023 Fall 2022 Spring 2022 Fall 2021 Spring 2021 Fall 2020 Spring 2020 Fall 2019 Spring 2019 Fall 2018 Spring 2018 Fall 2017 Spring 2017 Fall 2016 Spring 2016 Fall 2015 Summer 2015 Spring 2015 Spring 2014 Fall 2014

Medical Schools 40

Medical Schools Vaccine Virus 40

The Pharma Data

MARCH 11, 2021

Increased access to diagnostic testing and monitoring for HIV and hepatitis C virus (HCV) provides broader reliable solutions to patients living in remote settings. Since we launched the Global Access Program in 2014, access to innovative diagnostics solutions has improved in countries with high disease burdens.

Disease 52

Disease Treatment Laboratories Virus 52

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”.

Vaccine 52

Vaccine Research Virus Disease 52

PPD

OCTOBER 24, 2024

Hepatitis B virus (HBV) infection remains a significant public health challenge, particularly in low- and middle-income countries (LMIC) and in the Asia-Pacific region. A study showed that the prevalence of HBV surface antigen (HBsAg) among children under 5 years old decreased from 9.67% in 1992 to 0.32% in 2014.

Vaccine 52

Vaccine Virus Treatment Disease 52

Codon

DECEMBER 12, 2024

Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. The rabies virus infects most mammals and typically spreads through saliva (delivered via animal bites). Not all pathogens spread quickly.

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

OCTOBER 27, 2020

Since 2014, Dr. Clynes has led clinical development of checkpoint, CD3 bi-specifics and cytokine programs in immunotherapy at Bristol Myers Squibb and at Xencor, where he is currently VP Translational Biology and oversees seven immunotherapeutic assets currently in clinical development for cancer and autoimmunity. OSLO, Norway , Oct.

Virus 40

Virus Engineering Clinical Development International 40

The Pharma Data

AUGUST 31, 2020

About the cobas HIV-1/HIV-2 Qualitative Test cobas HIV-1/HIV-2 Qualitative for use on the cobas 6800/8800 Systems is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma. . Published 2014 Aug 26.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

JANUARY 12, 2021

About LumiraDx LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott , Ph.D., The LumiraDx SARS-CoV-2 Antigen test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein. and Alere Inc.

Laboratories 52

Laboratories Virus FDA Marketing 52

The Pharma Data

JULY 8, 2021

2014; 43: 343-73. 2014; 40 (4): 364-372. 2014; 12; 24: 14009. 2014; 133: 388-94. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) Chung KF, et al. Eur Respir J. Fernandes AG, et al. J Bras Pneumol. N Engl J Med.

FDA 52

FDA Trials Therapies Treatment 52

Drug Target Review

MAY 22, 2024

In parallel, we are exploring the technical performance of circVec in other viral vectors, as well as non-viral approaches which we expect will surpass virus-based vector-format as the state-of-the-art solutions for gene therapy in the future. So far, we have successfully expressed circRNA from six different vector types.

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

JANUARY 20, 2021

About LumiraDx LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott , Ph.D., The LumiraDx SARS-CoV-2 Antigen Test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein. and Alere Inc.

Virus 52

Virus Hospitals FDA Pharmaceuticals 52

The Pharma Data

OCTOBER 21, 2020

Six patients developed an infection with cytomegalovirus (a herpes virus), and four had a drop in white blood cells. When it came to market in 2014, the price tag for one treatment cycle was $89,000. It’s too soon to say this is a cure.” ” What does seem clear is that the regimen is less toxic than aggressive chemo.

Therapies 52

Therapies Drugs Treatment Trials 52

The Pharma Data

OCTOBER 21, 2020

Six patients developed an infection with cytomegalovirus (a herpes virus), and four had a drop in white blood cells. When it came to market in 2014, the price tag for one treatment cycle was $89,000. It’s too soon to say this is a cure.” ” What does seem clear is that the regimen is less toxic than aggressive chemo.

Therapies 52

Therapies Drugs Treatment Trials 52

Drug Target Review

MARCH 21, 2024

Because mRNA is not a virus, it doesn’t have to meet biosafety requirements for manufacturing and administration that an AAV approach would need. 2014 Jan 1;3. We plan to conduct additional safety studies as the programme progresses. Of note, mRNA is redosable as opposed to AAV. Molecular Therapy-Nucleic Acids.

Therapies 64

Therapies RNA Immune Response Treatment 64

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

2014 Jan 9;8(1):e2628. [2] Caption: Cyclic peptide (middle) binds to iPGM (blue). Credit: National Center for Advancing Translational Sciences, NIH When you think of the causes of infectious diseases, what first comes to mind are probably viruses and bacteria. PLoS Negl Trop Dis.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Codon

JUNE 13, 2024

But those studies were criticized in 2014 when researchers claimed that the earlier methods used “a rough biochemical approach…now considered to be unreliable for accurate genome size determinations.” The HK97 virus, for example, infects E. In the 1960s, biochemists clocked its genome at a whopping 300 billion bases.

DNA 60

DNA Molecular Biology Virus Cell Biology 60

The Pharma Data

DECEMBER 3, 2020

Today, transplant patients who do not respond or experience adverse events related to existing therapies may be at higher risk for complications from the virus, including transplant failure and death. 3 CMV is a ubiquitous virus that typically resides latent and asymptomatic in the body but reactivates during periods of immunosuppression.

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

Codon

JUNE 25, 2024

eLife (2014). The researchers chose to discard genes that encode virus-sensing machinery because the cells would be grown in a sterile laboratory environment. A molecular model showing FtsZ proteins (in green and red), extracted from a microbe called Staphylococcus aureus , constricting a liposome (blue). Credit: Szwedziak P.

DNA 80

DNA RNA Laboratories Research 80

The Pharma Data

JUNE 30, 2021

The primary endpoint is event-free survival (EFS), defined as the time from randomization to the earliest date of disease progression per Lugano Classification (Cheson et al, 2014), commencement of new lymphoma therapy, or death from any cause as determined by blinded central review.

Therapies 52

Therapies Treatment Virus Vaccine 52

The Pharma Data

JANUARY 18, 2021

Napoleone Ferrara, a member of OKYO’s Scientific Advisory Board, will be spearheading this effort at OKYO to advance chemerin and its associated analogues for the treatment of patients with SARS-CoV-2 virus and ARDS. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. .

Science 40

Science Virus Treatment Disease 40

The Pharma Data

NOVEMBER 9, 2020

Eur Respir J 2014; 43: 343–73. NPJ Prim Care Respir Med 2014; 12; 24: 14009. 2014; 133: 388–94. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. 9 Price D, Fletcher M, van der Molen T. 10 World Allergy Organization (WAO).

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

NOVEMBER 19, 2020

2014), 281, 4085-4096. The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. References. Hilgenfeld, Febs J. Pillaiyar, et al, J. 2016), 59, 6595-6628.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Codon

JUNE 11, 2024

The trio released the first nanopore-based sequencing device, the minION, in 2014. Hagan Bayley—a member of the Scripps team that used hairpins, in 2005, to slow down DNA passing through a nanopore—founded a company called Oxford Nanopore , alongside Gordon Sanghera and Spike Willcocks, that same year.

DNA 83

DNA Engineering RNA Small Molecule 83

The Pharma Data

OCTOBER 22, 2020

Last year there were 176 WPV1 cases, the highest number reported since the PHEIC was declared in 2014, when there were 359 cases in nine countries. The same virus has also been detected in sewage in Cairo, Egypt but with no evidence of local circulation. Cross border spread of cVDPV2 is now occurring regularly.

Vaccine 52

Vaccine International Immune Response Virus 52

Codon

JULY 27, 2023

In 2014, some clever engineers figured out how to express these gas vesicles in other types of cells and also showed that they produce contrast on ultrasound images. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

In 2014, some clever engineers figured out how to express these gas vesicles in other types of cells and also showed that they produce contrast on ultrasound images. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

Metabolite Tales Blog

JULY 5, 2023

20 (March 20, 2014). link] [6] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION Study NC219 [link] [7] Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. Ayushi Jain and Khalid Mumtaz, 2022. Avicenna J Med 12:154–156.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

20 (March 20, 2014). link] [6] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION Study NC219 [link] [7] Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. Ayushi Jain and Khalid Mumtaz, 2022. Avicenna J Med 12:154–156.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

3 Evidence on transmission of hepatitis C virus (HCV) is less clear, but in Europe, where SSPs are more widely used, high SSP use is associated with a 76% reduction in HCV transmission. 2014 Feb;43(1):235-48. 2014 Sep;25(5):905-10. Epub 2014 May 21. 2014 Nov;18(11):2144-55. fold return on investment. 2014.05.008.

Drugs 120

Drugs Treatment Disease Science 120

The Pharma Data

DECEMBER 21, 2020

2014; 43 (2): 343-373. About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Am J Respir Crit Care Med.

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

FEBRUARY 22, 2021

You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay. Serious infections have happened in some people taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Access Economics Pty Limited. Mehta F.

Disease 52

Disease Treatment Therapies Trials 52